


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED 5.28.03

MAY 23 2003  
TECH CENTER 1600/2900



Applicants : Peter D. Kwong et al.  
Serial No. : 09/856,200  
Filed : January 3, 2003  
For : CRYSTAL COMPRISING HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEIN GP120, COMPOUNDS INHIBITING CD4-GP120 INTERACTION, COMPOUNDS INHIBITING CHEMOKINE RECEPTOR-GP120 INTERACTION, MIMICS OF CD4 AND GP120 VARIANTS

1135 Avenue of the Americas  
New York, New York 10036  
May 9, 2003

Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22312-1450  
Mail Stop OIPE

Sir:

COMMUNICATION TO CORRECT ERROR IN FILING RECEIPT

This Communication is filed to request the issuance of a corrected Filing Receipt in connection with the above-identified application. Upon receipt of the official Filing Receipt for the subject application, a copy of which is attached hereto as **Exhibit A**, applicants' undersigned attorney noticed an error.

Specifically, the Domestic Priority data is listed incorrectly on the enclosed Filing Receipt.

A corrected filing receipt should read as follows:

--Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US98/23905 11/10/1998  
a CIP of 09/100,631 06/18/1998 ABN  
which is a CIP of 08/976,741 11/24/1997 ABN  
and a CIP of 09/100,763 06/18/1998 ABN  
which is a CIP of 08/966,987 11/10/1997 ABN

Applicants: Peter D. Kwong et al.  
Serial No.: 09/856,200  
Filed: January 3, 2003  
Page 2

and a CIP of 09/100,529 06/18/1998  
which is a CIP of 08/967,403 11/10/1997 ABN  
and a CIP 09/100,762 06/18/1998 ABN  
which is a CIP of 08/966,932 11/10/1997 ABN  
and a CIP of 09/100,521 06/18/1998 ABN  
which is a CIP of 08/967,148 11/10/1997 ABN


Applicants contend that the correct data may be found in the Preliminary Amendment filed May 7, 2001 in connection with the subject application. A copy of the Preliminary Amendment is attached hereto as **Exhibit B**. Accordingly, applicants request that a corrected Filing Receipt be issued.

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Arlington, VA 22213-1450

  
John F. White  
Reg. No. 28,678

8/9/03  
Date

John F. White  
Registration No. 28,678  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400



UNITED STATES  
PATENT AND  
TRADEMARK OFFICE

Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/856,200 ✓	01/03/2003 ✓	1645	968	54203-H- PCT- US/JPW/SHS	197	12	11

John P White  
Cooper & Dunham  
1185 Avenue of the Americas  
New York, NY 10036



CONFIRMATION NO. 3857

FILING RECEIPT



\*OC000000009873732\*

Date Mailed: 04/23/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Peter D. Kwong, New York, NY;  
Wayne A. Hendrickson, Hasting-on-Hudson, NY;  
Joseph G. Sodroski, Medford, MA;  
Richard T. Wyatt, Andover, MA;

RECEIVED

MAY 23 2003  
TECH CENTER 1600/2900

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US98/23905 11/10/1998  
which is a CIP of 08/966,987 11/10/1997 ABN

Foreign Applications

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Crystal comprising human immunodeficiency virus envelope glycoprotein gp120, compounds inhibiting cd4-gp 120 interaction, compounds inhibiting chemokine receptor-gp120 interaction, mimics of cd4 and gp120 variants

**Preliminary Class**

514

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).